Market Place
Sourcing Support
4DMT To Participate In Upcoming Investor Meetings
16 Mar 2026 //
GLOBENEWSWIRE
4DMT Reveals Positive 60-Week 4D-150 SPECTRA Trial Results in DME
31 Jul 2025 //
GLOBENEWSWIRE
4DMT Presents at American Society of Retina Specialists Meeting
24 Jul 2025 //
GLOBENEWSWIRE
4DMT to Participate in Upcoming Investor Conferences
28 May 2025 //
GLOBENEWSWIRE
4DMT to Participate in Upcoming Investor Conferences
19 Feb 2025 //
GLOBENEWSWIRE
4DMT restructures pipeline, extending cash runway through 2028
10 Jan 2025 //
FIERCE BIOTECH
Investors sour on 4DMT`s wet AMD gene therapy results, stock tumbles
18 Jul 2024 //
PRESS RELEASE
4DMT Reports Positive Phase 2 Data For 4D-150 In Wet AMD
17 Jul 2024 //
GLOBENEWSWIRE
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 at Summit
07 Jun 2024 //
GLOBENEWSWIRE
4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
04 Jun 2024 //
GLOBENEWSWIRE
4DMT to Participate in Upcoming Investor Conferences
03 Jun 2024 //
GLOBENEWSWIRE
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
09 May 2024 //
GLOBENEWSWIRE
4DMT to Participate in Upcoming Investor Conference
07 May 2024 //
GLOBENEWSWIRE
4DMT Announces Presentations at ARVO 2024 Annual Meeting
01 May 2024 //
GLOBENEWSWIRE
4DMT to Participate in Upcoming Investor Conferences
04 Mar 2024 //
GLOBENEWSWIRE
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
29 Feb 2024 //
GLOBENEWSWIRE
4D Molecular Announces Pricing of Upsized Public Offering of Common Stock
06 Feb 2024 //
GLOBENEWSWIRE
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
05 Feb 2024 //
GLOBENEWSWIRE
4DMT Highlights Recent Clinical Pipeline Progress
04 Jan 2024 //
GLOBENEWSWIRE
4DMT to Participate in Upcoming Investor Conferences
15 Nov 2023 //
GLOBENEWSWIRE
4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
09 Nov 2023 //
GLOBENEWSWIRE
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Trial of Aerosolized
01 Nov 2023 //
GLOBENEWSWIRE
4DMT to Present Data fromPhase 1/2 Trial for Cystic Fibrosis at 2023 NACFC
25 Oct 2023 //
GLOBENEWSWIRE
4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
12 Sep 2023 //
GLOBENEWSWIRE
4DMT to Participate in Upcoming Investor Conferences
07 Sep 2023 //
GLOBENEWSWIRE
4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
01 Jun 2023 //
GLOBENEWSWIRE
4D Molecular Therapeutics Reports 1Q 2023FYR &Operational Highlights
10 May 2023 //
GLOBENEWSWIRE
4D Molecular Therapeutics Announces Closing of Upsized Public Offering
09 May 2023 //
GLOBENEWSWIRE
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
08 May 2023 //
GLOBENEWSWIRE
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
04 May 2023 //
GLOBENEWSWIRE
4D Molecular Therapeutics Announces Pricing of Upsized PO of Common Stock
04 May 2023 //
GLOBENEWSWIRE
4D Molecular Reports Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
4D Molecular to Participate in the SVB Securities Global Biopharma Conference
08 Feb 2023 //
GLOBENEWSWIRE
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150
02 Feb 2023 //
GLOBENEWSWIRE
4D Molecular Announces Updates on Pipeline and Preclinical Programs
09 Jan 2023 //
GLOBENEWSWIRE
4D Molecular to Participate in the Evercore ISI HealthCONx 2022 Conference
21 Nov 2022 //
GLOBENEWSWIRE
4D Molecular (FDMT) Stock Up 178% in One Month: Here`s Why
17 Nov 2022 //
FINANCE YAHOO
4D Molecular Announces Data from Phase 1/2 Trial of Intravitreal 4D-150
14 Nov 2022 //
PRESS RELEASE
4D Molecular Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150
10 Nov 2022 //
PRESS RELEASE
4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results
09 Nov 2022 //
GLOBENEWSWIRE
4D Molecular Announces Interim Clinical Data from Phase 1/2 Trial of 4D-710
03 Nov 2022 //
GLOBENEWSWIRE
4D Molecular Interim Data from the On-going Phase 1/2 Clinical Trial of 4D-710
26 Oct 2022 //
GLOBENEWSWIRE
4D Molecular Therapeutics Appoints Noriyuki Kasahara to the BOD
27 Sep 2022 //
GLOBENEWSWIRE
4D Molecular Appoints Noriyuki Kasahara, MD, PhD to the BOD
27 Sep 2022 //
GLOBENEWSWIRE
4D Molecular Therapeutics Reports Q2 2022 Result and Provides 4D-310
11 Aug 2022 //
GLOBENEWSWIRE
4D Molecular Therapeutics to Participate in Upcoming June Investor Conferences
02 Jun 2022 //
GLOBENEWSWIRE
4D Molecular Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
4D Molecular Therapeutics to Participate in the BofA Securities 2022 Conference
05 May 2022 //
GLOBENEWSWIRE
4D Molecular Begins Dosing in Phase 1/2 Trial of 4D-710 for Cystic Fibrosis
04 Apr 2022 //
GLOBENEWSWIRE
4D Molecular Therapeutics Reports Full Year 2021 Financial Results
28 Mar 2022 //
GLOBENEWSWIRE
4D Molecular Therapeutics Announces Resignation of Professor David Schaffer
22 Feb 2022 //
GLOBENEWSWIRE
4D Molecular Therapeutics to Participate in 11th Annual SVB Leerink Conference
11 Feb 2022 //
GLOBENEWSWIRE
4D Molecular Tx Announces Updated Interim Results from 4D-310 Phase 1/2 Trial
09 Feb 2022 //
GLOBENEWSWIRE
FDA Grants FTD to 4D Molecular`s 4D-125 in X-linked Retinitis Pigmentosa
10 Jan 2022 //
GLOBENEWSWIRE
4D Molecular Begins Dosing in Phase 1/2 Clinical Trial of 4D-150 in wet AMD
06 Jan 2022 //
GLOBENEWSWIRE
4D Molecular Therapeutics Reports Financial Results for the 3Q of 2021
10 Nov 2021 //
GLOBENEWSWIRE
4D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock
28 Oct 2021 //
GLOBENEWSWIRE
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
26 Oct 2021 //
GLOBENEWSWIRE
4D Molecular Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial
25 Oct 2021 //
GLOBENEWSWIRE
